Buchumschlag

Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164

Background - Pembrolizumab demonstrated durable clinical benefit and manageable safety in previously treated advanced or metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer (CRC) in the phase 2 KEYNOTE-164 study. Results from the final analysis are p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Le, Dung T. (VerfasserIn) , Diaz, Luis A. (VerfasserIn) , Kim, Tae Won (VerfasserIn) , Van Cutsem, Eric (VerfasserIn) , Geva, Ravit (VerfasserIn) , Jäger, Dirk (VerfasserIn) , Hara, Hiroki (VerfasserIn) , Burge, Matthew (VerfasserIn) , O’Neil, Bert H. (VerfasserIn) , Kavan, Petr (VerfasserIn) , Yoshino, Takayuki (VerfasserIn) , Guimbaud, Rosine (VerfasserIn) , Taniguchi, Hiroya (VerfasserIn) , Élez, Elena (VerfasserIn) , Al-Batran, Salah-Eddin (VerfasserIn) , Boland, Patrick M. (VerfasserIn) , Cui, Yi (VerfasserIn) , Leconte, Pierre (VerfasserIn) , Marinello, Patricia (VerfasserIn) , André, Thierry (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: June 2023
In: European journal of cancer
Year: 2023, Jahrgang: 186, Pages: 185-195
ISSN:1879-0852
DOI:10.1016/j.ejca.2023.02.016
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejca.2023.02.016
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804923001089
Volltext
Verfasserangaben:Dung T. Le, Luis A. Diaz, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert H. O’Neil, Petr Kavan, Takayuki Yoshino, Rosine Guimbaud, Hiroya Taniguchi, Elena Élez, Salah-Eddin Al-Batran, Patrick M. Boland, Yi Cui, Pierre Leconte, Patricia Marinello, Thierry André
Beschreibung
Zusammenfassung:Background - Pembrolizumab demonstrated durable clinical benefit and manageable safety in previously treated advanced or metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer (CRC) in the phase 2 KEYNOTE-164 study. Results from the final analysis are presented. - Methods - Eligible patients had unresectable or metastatic MSI-H/dMMR CRC and ≥2 prior systemic therapies (cohort A) or ≥1 prior systemic therapy (cohort B). Patients received pembrolizumab 200mg intravenously every 3 weeks for ≤35 cycles. The primary end-point was objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors, version 1.1 by blinded independent central review. Secondary end-points included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety and tolerability. - Results - Sixty-one patients in cohort A and 63 patients in cohort B were enroled; median follow-up was 62.2 months and 54.4 months, respectively. ORR was 32.8% (95% CI, 21.3%-46.0%) in cohort A and 34.9% (95% CI, 23.3%-48.0%) in cohort B. Median DOR was not reached (NR) in either cohort. Median PFS was 2.3 months (95% CI, 2.1-8.1) in cohort A and 4.1 months (95% CI, 2.1-18.9) in cohort B. Median OS was 31.4 months (95% CI, 21.4-58.0) in cohort A and 47.0 months (95% CI, 19.2-NR) in cohort B. No new safety signals were observed. Nine patients who initially responded experienced disease progression off therapy and received second-course pembrolizumab. Six patients (66.7%) completed an additional 17 cycles of pembrolizumab, and 2 patients achieved a partial response. - Conclusions - Pembrolizumab continued to show durable antitumor activity, prolonged OS, and manageable safety in patients with previously treated MSI-H/dMMR CRC. - Clinical Trial Registry Information - ClinicalTrials.gov, NCT02460198
Beschreibung:Online verfügbar: 24. Februar 2023, Artikelversion: 2. Mai 2023
Gesehen am 16.08.2023
Beschreibung:Online Resource
ISSN:1879-0852
DOI:10.1016/j.ejca.2023.02.016

Ähnliche Einträge